You are here: Industry Insights > TRASTUZUMAB

News List

WHO announces first biosimilar medicine pre-qualification europeanpharmaceuticalreview
January 03, 2020
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
Mylan, Biocon Launch Trastuzumab Biosimilar, Ogivri in the U.S. americanpharmaceuticalreview
December 30, 2019
Mylan and Biocon announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab).
Two Drugs Make Inroads Against Aggressive Breast Cancers drugs
December 12, 2019
Two experimental drugs show real promise against an aggressive, treatment-resistant form of breast cancer that's spread to other parts of the body, researchers say.
Pertuzumab, Trastuzumab Combination with ENHANZE Drug Delivery Meets Primary Endpoint americanpharmaceuticalreview
September 17, 2019
Halozyme announced the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.
Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar in the Russian Federation b3cnewswire
July 09, 2019
Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar in the Russian Federation.
Prestige BioPharma Reports Positive Top-Line Phase III Results for Tuznue® (Trastuzumab Biosimilar) b3cnewswire
June 24, 2019
Prestige BioPharma announced positive top-line results from a Phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics (PK) of biosimilar candidate HD201 to Herceptin (trastuzumab).
European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review b3cnewswire
May 29, 2019
European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review.
Super-blockbuster: Trastuzumab PharmaSources/1℃
May 14, 2019
As one of the three super-blockbusters of Roche, trastuzumab has accumulatively brought over CHF80 billion sales revenue.
Based on China to Go International: The Trastuzumab Biosimilar HLX02 Applied for Marketing PharmaSources/1℃
May 14, 2019
The marketing of the drug in China will mark a milestone.
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer worldpharmanews
May 10, 2019
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer.

Previous page 1 2 3 Next page